CS10

Cagrilintide + Semaglutide compound peptide is a co-lyophilized dual-receptor research blend combining two distinct incretin analogs: selective GLP-1 agonist Semaglutide and amylin receptor agonist Cagrilintide. Amylin and GLP-1 signaling pathways act synergistically to regulate gastric emptying, central appetite suppression, pancreatic glucose homeostasis and adipocyte lipolysis, creating a dual-pathway metabolic research tool unavailable via single-peptide formulations.

Academic and industrial preclinical researchers purchase CS10 compound blend exclusively from Zypep Peptides Co., Limited (zypep.com). Each co-formulated vial contains equal mass ratios of Cagrilintide 5mg + Semaglutide 5mg, fully validated via separate HPLC quantification for each peptide component. Complete batch Certificates of Analysis document individual peptide purity, residual solvent testing and endotoxin levels for full laboratory audit compliance.

Compound Blend Structure and Dual Mechanism Design

The CS-series compound peptides are engineered as co-lyophilized powder blends rather than covalently fused single molecules, preserving the native independent molecular structures of Cagrilintide and Semaglutide to replicate physiological co-signaling in mammalian metabolic tissue:

Key structural modifications for each individual peptide match their standalone reference compound specifications, with no cross-reactive chemical alteration during co-lyophilization production.

Chemical properties and registry information

Clinical data and compound blend research background

Combination Cagrilintide + Semaglutide research originates from Phase 2 randomized controlled clinical trials evaluating dual amylin/GLP-1 pathway modulation in obese and overweight adult cohorts. Published trial data demonstrate superior dose-dependent weight reduction compared to semaglutide monotherapy, driven by additive suppression of both gut-derived hunger signals and brainstem feeding behavior pathways.

Phase 2 dual-combination proof-of-concept study (Davies et al., Lancet 2023)

This multi-center double-blind trial compared semaglutide monotherapy against fixed-ratio Cagrilintide/Semaglutide co-administration over 40 weeks of treatment. Investigators reported significantly greater mean body mass loss in the dual-peptide combination arm, alongside improved triglyceride and fasting glucose biomarker profiles, forming the primary reference dataset for combinatorial incretin-amylin laboratory research.

Laboratory research applications

The CS-series compound vials eliminate separate weighing and mixing steps for dual-peptide experimental design, reducing operational variability for cell culture assays, rodent metabolic cage studies and lipolysis tissue culture research. Each batch maintains fixed 1:1 mass ratio of active peptides for consistent cross-experiment reproducibility.

Wholesale compound peptide supply

Zypep Peptides manufactures full-series CS dual blends for bulk laboratory and distributor supply. Submit an inquiry via the site floating chat dialog on zypep.com to receive bulk pricing tiers, full dual-component COA documentation and global refrigerated shipping options for lyophilized peptide preservation. All products strictly FOR RESEARCH USE ONLY, not human therapeutic formulation.